NCT06847867: A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
- State
- Under way
- Phase
- Phase 2
- People
- 80 planned
- Started
- 5 Jun 2025
- Primary completion
- 14 Jul 2027
- Arms
- Momelotinib dose level 1, Momelotinib dose level 2
- Results
- None posted
- 26 Feb 2025: Trial registered
- 5 Jun 2025: Trial started